Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study.

Abstract

We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.

• Authors: Gloria Dalla Costa, Letizia Leocani, Xavier Montalban, Ana Isabel Guerrero, Per Soelberg Sørensen, Melinda Magyari, Richard J B Dobson, Nicholas Cummins, Vaibhav A Narayan, Matthew Hotopf, Giancarlo Comi, RADAR-CNS consortium
• Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (Neurol Sci) Vol. 41 Issue 7 Pg. 1647-1650 (Jul 2020) ISSN: 1590-3478 [Electronic] Italy
• PMID: 32617741 (Publication Type: Journal Article)

Chemical References

• Alemtuzumab

Topics

• Adult
• Alemtuzumab (therapeutic use)
• Betacoronavirus
• COVID-19
• Coronavirus Infections (drug therapy, epidemiology)
• Europe
• Female
• Humans
• Longitudinal Studies
• Male
• Middle Aged
• Multiple Sclerosis (complications, epidemiology, virology)
• Pandemics
• Pneumonia, Viral (drug therapy, epidemiology)
• Prevalence
• SARS-CoV-2